You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

Drug Price Trends for NDC 00781-3234


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00781-3234

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for Glatopa (NDC: 0781-3234)

Introduction to Glatopa

Glatopa, with the NDC code 0781-3234, is a generic version of Copaxone, a glatiramer acetate injection used primarily for the treatment of relapsing forms of multiple sclerosis (MS). It is a clear, colorless to slightly yellow, sterile, nonpyrogenic solution available in 1 mL single-dose glass syringes[1].

Market Context

Pharmaceutical Industry Trends in 2024

The pharmaceutical industry in 2024 is characterized by several key trends that influence the market dynamics of drugs like Glatopa.

  • Continued Dominance of Small Molecule Drugs: Although Glatopa is a biologic, the overall pharmaceutical market is still dominated by small molecule drugs, which account for over 54.9% of global sales. This dominance is due to the ease of manufacturing, formulation, and administration, as well as the lower cost compared to biologics[2].

  • Increasing Adoption of Biologics: Despite the dominance of small molecule drugs, biologics like Glatopa are gaining traction. The outsourcing of drug development and manufacturing to Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) is expected to grow, which can impact the production and pricing of biologics[2].

  • Growing Demand for Personalized Medicine: The use of AI and advanced data analysis is driving the demand for personalized medicine. While Glatopa is not a personalized medicine per se, the trend towards more tailored treatments could influence how patients and healthcare providers choose between different MS treatments[2].

Market Drivers

High Demand for MS Treatments

Multiple sclerosis is a chronic and debilitating disease with a significant patient population. The demand for effective treatments like Glatopa remains high, driven by the need for managing symptoms and slowing disease progression.

Generic Competition

As a generic version of Copaxone, Glatopa benefits from the expiration of patents on the original drug. Generic competition often leads to lower prices, making the drug more accessible to a wider patient population.

Market Restraints

Regulatory Environment

The pharmaceutical industry, including biologics like Glatopa, is heavily regulated. Stringent regulatory policies can affect the approval and pricing of drugs. For instance, any changes in regulatory requirements or approval processes can impact the market availability and pricing of Glatopa[3].

R&D Costs

The development and manufacturing of biologics are costly. These high costs can be passed on to consumers, affecting the pricing strategy for Glatopa. However, generic status often mitigates some of these costs, leading to more competitive pricing[2].

Price Projections

Current Market Pricing

As of the current market analysis, the pricing of Glatopa is influenced by its generic status and the competitive landscape. Generic drugs typically offer significant cost savings compared to their brand-name counterparts.

Future Pricing Trends

  • Generic Competition: As more generic versions of Copaxone enter the market, competition is likely to increase, driving prices down. This trend is expected to continue, making Glatopa and similar generics more affordable for patients[2].

  • Healthcare Policies: Changes in healthcare policies, especially those related to drug pricing and reimbursement, can significantly impact the market price of Glatopa. For example, policies aimed at reducing drug costs could lead to lower prices for patients[3].

  • Economic Factors: Economic conditions, such as inflation and changes in healthcare spending, can also influence the pricing of pharmaceuticals. In times of economic uncertainty, patients may seek more cost-effective options, further driving the demand for generics like Glatopa.

Key Takeaways

  • Market Demand: The demand for MS treatments remains high, ensuring a stable market for Glatopa.
  • Generic Status: As a generic drug, Glatopa benefits from lower production costs and competitive pricing.
  • Regulatory Environment: Stringent regulations can impact the approval and pricing of biologics.
  • Future Trends: Increased competition from other generics and changes in healthcare policies are expected to influence pricing.

FAQs

Q: What is Glatopa used for? A: Glatopa is used for the treatment of relapsing forms of multiple sclerosis (MS).

Q: Is Glatopa a brand-name or generic drug? A: Glatopa is a generic version of the brand-name drug Copaxone.

Q: How does the pricing of Glatopa compare to Copaxone? A: As a generic, Glatopa is generally priced lower than Copaxone.

Q: What are the key factors influencing the price of Glatopa? A: The price of Glatopa is influenced by generic competition, regulatory policies, R&D costs, and healthcare policies.

Q: Are there any upcoming trends that could affect the pricing of Glatopa? A: Yes, trends such as increased generic competition, advancements in personalized medicine, and changes in healthcare policies could impact the pricing of Glatopa.

Sources

  1. DailyMed: GLATOPA- glatiramer acetate injection, solution - DailyMed
  2. Global Pharma Tek: Top 12 Pharmaceutical Industry Trends in 2024
  3. GlobeNewswire: U.S. OTC Drugs Market Forecast Report 2024-2029: Shares of Key Players, Industry Trends, Statistics, and Growth Forecasts by Product Type, Formulation Type, and Distribution Channel.

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.